Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Feb 04, 2016 2:54pm
330 Views
Post# 24525270

RE:RE:shocker... THERAPURE

RE:RE:shocker... THERAPURE
Completely agree on the optics.    But having said that,  if GMP and CIBC put their firm's reputations behind a $1B valuation for Therapure,  then they have to think they would defend a PLI valution of $5B PLUS given the relative merits of the companies.   Therapure is MILES behind PLI,  looking at commodity fractionation products,  and otherwise trying to copy PLI's business model.   From what we understand,  they havent even scaled up the commercial process....   a process which Celgene dropped deeming it uneconomical.   Looks like a nice webpage with lipstick on a pig to me.  Looks good on Catalyst after they were such a pleasure to deal with many years ago.

There has been alot of talk about CIBC coverage initiation.   Perhaps this IPO effort was a conflict slowing down the initiation.  Now that this IPO is dropped indefinitely,  I have to take the glass-half-full view that CIBC Is now going to initiate coverage with a huge valuation target on PLI... if nothing else,  based on what they justified and were trying to sell on Therapure
Bullboard Posts